BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours
Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Heudobler D, Borchmann P, Bokemeyer C, Klobuch S, Smit E, Mueller F, Desuki A, Lueke F, Wiegert E, Flemmig C, Schulz-Eying C, Rengstl B, Preussner L, Tuereci O, Sahin U (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S1404-S1405
Conference Proceedings Title: ANNALS OF ONCOLOGY
Event location: , ELECTR NETWORK
DOI: 10.1016/j.annonc.2022.08.035
Authors with CRIS profile
Involved external institutions
Netherlands Cancer Institute (NKI)
Netherlands (NL)
Universitätsklinikum Regensburg
Germany (DE)
BioNTech / Biopharmaceutical New Technologies
Germany (DE)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Bexon Clinical Consulting
United States (USA) (US)
Universitätsklinikum Köln
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Netherlands (NL)
Universitätsklinikum Regensburg
Germany (DE)
BioNTech / Biopharmaceutical New Technologies
Germany (DE)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Bexon Clinical Consulting
United States (USA) (US)
Universitätsklinikum Köln
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
How to cite
APA:
Mackensen, A., Haanen, J.B.A.G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D.,... Sahin, U. (2022). BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours. In ANNALS OF ONCOLOGY (pp. S1404-S1405). , ELECTR NETWORK: AMSTERDAM: ELSEVIER.
MLA:
Mackensen, Andreas, et al. "BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours." Proceedings of the Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), , ELECTR NETWORK AMSTERDAM: ELSEVIER, 2022. S1404-S1405.
BibTeX: Download